Clinical Trials · NCT05024032
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 210
- Start date
- Sep 2021
- Locations
- 29 sites, China
- Primary endpoint
- Mean Percent Change From Baseline in Body Weight